Wolf, D <br/><br/>
Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis.  [electronic resource] 

 -  Alimentary pharmacology & therapeutics  Sep 2014 
 - 486-97 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1365-2036 
<br/><br/><label>Standard No.: </label>10.1111/apt.12863  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adalimumab<br/>Adult<br/>Anti-Inflammatory Agents--administration & dosage<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Colitis, Ulcerative--drug therapy<br/>Double-Blind Method<br/>Drug Administration Schedule<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Treatment Outcome<br/>Tumor Necrosis Factor-alpha--antagonists & inhibitors